{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:54:51Z","timestamp":1781848491390,"version":"3.54.5"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Fecal microbiota transplantation (FMT) has emerged as a promising therapeutic approach for ulcerative colitis (UC). This single-center retrospective cohort study evaluated the clinical effectiveness and safety of an optimized FMT protocol, in which donor bacteria were concentrated by tangential-flow micropore membrane filtration and delivered after pre-FMT antibiotic preconditioning, as adjunctive therapy in adults with mild-to-moderate UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed prospectively collected data from 156 patients with mild-to-moderate active UC treated between December 2022 and December 2024. Treatment allocation was determined by a shared clinical decision between the gastroenterologist and patient based on disease severity, prior medication exposure, and patient preference. Patients were grouped into four pre-specified treatment strata: aminosalicylates alone (Group A,\n                      <jats:italic>n<\/jats:italic>\n                      = 42), aminosalicylates plus corticosteroids\/immunosuppressants (Group B,\n                      <jats:italic>n<\/jats:italic>\n                      = 38), aminosalicylates plus FMT (Group FMT1,\n                      <jats:italic>n<\/jats:italic>\n                      = 40), and aminosalicylates plus corticosteroids\/immunosuppressants plus FMT (Group FMT2,\n                      <jats:italic>n<\/jats:italic>\n                      = 36). Donor stools were processed using a validated tangential-flow 0.22-\u03bcm membrane filtration workflow that retains and concentrates viable bacteria in the retentate while clearing soluble metabolites and host debris in the permeate. Confounding was addressed using multivariable logistic regression and inverse probability of treatment weighting (IPTW) as a sensitivity analysis. The primary outcome was clinical response at 12 weeks; effect sizes are reported as risk differences with 95% confidence intervals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Clinical response rates at 12 weeks were 31.0% (Group A), 52.6% (Group B), 72.5% (Group FMT1), and 77.8% (Group FMT2). Clinical remission rates were 19.0%, 34.2%, 55.0%, and 61.1%, respectively. FMT-containing regimens were associated with higher response and remission than aminosalicylates alone (risk difference for response: 41.5%, 95%\n                      <jats:italic>CI<\/jats:italic>\n                      22.7\u201360.3% for FMT1 vs. A; 46.8%, 95%\n                      <jats:italic>CI<\/jats:italic>\n                      28.0\u201365.6% for FMT2 vs. A; both\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Microbiome analysis using 16S rRNA gene sequencing showed that responders had increased Bacteroides-related amplicon sequence variants and increased alpha diversity comparable to donor profiles, while non-responders maintained dysbiotic profiles. Adverse events were mild and comparable across all groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective cohort, an optimized FMT protocol using membrane-filtered bacterial concentrates was associated with higher rates of clinical response, clinical remission and endoscopic improvement at 12 weeks compared with conventional therapy, with an acceptable short-term safety profile. Given the observational design, these findings should be interpreted as hypothesis-generating and require confirmation in randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1805799","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:47:47Z","timestamp":1781848067000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimized fecal microbiota transplantation using membrane-filtered bacterial concentrates as adjunctive therapy for mild-to-moderate ulcerative colitis: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Jie","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Shanghai Pudong New Area People's Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai Pudong New Area People's Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai Pudong New Area People's Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai Pudong New Area People's Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyun","family":"Hang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai Pudong New Area People's Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai Pudong New Area People's Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingmei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai Pudong New Area People's Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav. Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1038\/d41586-018-07276-2","article-title":"Ulcerative colitis: towards remission","volume":"563","author":"Eisenstein","year":"2018","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/ibd\/izac135","article-title":"Efficacy of fecal microbiota transplantation in the treatment of active ulcerative colitis: a systematic review and meta-analysis of double-blind randomized controlled trials","volume":"29","author":"El Hage Chehade","year":"2023","journal-title":"Inflamm. Bowel Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"14494","DOI":"10.1038\/s41598-023-41182-6","article-title":"Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis","volume":"13","author":"Feng","year":"2023","journal-title":"Sci. Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"689492","DOI":"10.1155\/2014\/689492","article-title":"The central role of the gut microbiota in chronic inflammatory diseases","volume":"2014","author":"Ferreira","year":"2014","journal-title":"J. Immunol. Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","article-title":"Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology","volume":"19","author":"Fuchs","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature12721","article-title":"Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells","volume":"504","author":"Furusawa","year":"2013","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41586-020-2025-2","article-title":"Pathway paradigms revealed from the genetics of inflammatory bowel disease","volume":"578","author":"Graham","year":"2020","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/1751-2980.12849","article-title":"Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment","volume":"21","author":"Guo","year":"2020","journal-title":"J. Dig. Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S2468-1253(21)00400-3","article-title":"Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Haifer","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.aca.2014.11.015","article-title":"An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography\u2013tandem mass spectrometry","volume":"854","author":"Han","year":"2015","journal-title":"Anal. Chim. Acta"},{"key":"B12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/MIB.0000000000000975","article-title":"Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis","volume":"23","author":"Ishikawa","year":"2017","journal-title":"Inflamm. Bowel Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1038\/s41467-019-13036-1","article-title":"Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis","volume":"10","author":"Johnson","year":"2019","journal-title":"Nat. Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1136\/gutjnl-2022-327811","article-title":"Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial","volume":"71","author":"Kedia","year":"2022","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/ibd\/izaf013","article-title":"Guidance for fecal microbiota transplantation trials in ulcerative colitis: the second ROME consensus conference","volume":"31","author":"Lopetuso","year":"2025","journal-title":"Inflamm. Bowel Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cmet.2020.09.004","article-title":"The gut microbiota at the service of immunometabolism","volume":"32","author":"Michaudel","year":"2020","journal-title":"Cell Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial","volume":"149","author":"Moayyedi","year":"2015","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1097\/MIB.0000000000001228","article-title":"Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis","volume":"23","author":"Narula","year":"2017","journal-title":"Inflamm. Bowel Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial","volume":"389","author":"Paramsothy","year":"2017","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.chom.2023.03.020","article-title":"Key determinants of success in fecal microbiota transplantation: from microbiome to clinic","volume":"31","author":"Porcari","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1053\/j.gastro.2016.10.012","article-title":"Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches","volume":"152","author":"Sartor","year":"2017","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.7861\/clinmed.2021-0080","article-title":"Ulcerative colitis: an update","volume":"21","author":"Segal","year":"2021","journal-title":"Clin. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1136\/gutjnl-2018-316250","article-title":"Microbiota fermentation-NLRP3 axis shapes the impact of dietary fibres on intestinal inflammation","volume":"68","author":"Singh","year":"2019","journal-title":"Gut"},{"key":"B26","doi-asserted-by":"publisher","first-page":"otaa067","DOI":"10.1093\/crocol\/otaa067","article-title":"Fecal microbiota transplantation for ulcerative colitis: an evolving therapy","volume":"2","author":"Sood","year":"2020","journal-title":"Crohns Colitis 360"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1049849","DOI":"10.3389\/fmed.2022.1049849","article-title":"Efficacy and safety of fecal microbiota transplantation via colonoscopy as add-on therapy in patients with mild-to-moderate ulcerative colitis: a randomized clinical trial","volume":"9","author":"Tkach","year":"2023","journal-title":"Front. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"802","DOI":"10.21037\/atm-22-3236","article-title":"Efficacy and safety of fecal microbiota transplantation for the induction of remission in active ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Wei","year":"2022","journal-title":"Ann. Transl. Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fcimb.2019.00002","article-title":"The super-donor phenomenon in fecal microbiota transplantation","volume":"9","author":"Wilson","year":"2019","journal-title":"Front. Cell. Infect. Microbiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/s41598-021-81628-3","article-title":"Dysbiosis of gut microbiota in Polish patients with ulcerative colitis: a pilot study","volume":"11","author":"Zakerska-Banaszak","year":"2021","journal-title":"Sci. Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"18558","DOI":"10.1038\/s41598-024-62463-8","article-title":"Sustained mucosal colonization and fecal metabolic dysfunction by Bacteroides associates with fecal microbial transplant failure in ulcerative colitis patients","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci. Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/jgh.16795","article-title":"Gut microbiome-targeted therapies as adjuvant treatments in inflammatory bowel diseases: a systematic review and network meta-analysis","volume":"40","author":"Zhang","year":"2025","journal-title":"J. Gastroenterol. Hepatol"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1805799\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:47:48Z","timestamp":1781848068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1805799\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":33,"alternative-id":["10.3389\/fmicb.2026.1805799"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1805799","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"1805799"}}